T. Rowe Price Investment Management, Inc. - ZENTALIS PHARMACEUTICALS INC ownership

ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 105 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.3%.

Quarter-by-quarter ownership
T. Rowe Price Investment Management, Inc. ownership history of ZENTALIS PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$39,569
-29.8%
1,972,484
-1.3%
0.03%
-26.3%
Q2 2023$56,402
+63.1%
1,999,354
-0.5%
0.04%
+52.0%
Q1 2023$34,580
-22.3%
2,010,409
-9.0%
0.02%
-26.5%
Q4 2022$44,519
-99.9%
2,210,442
+0.1%
0.03%
-10.5%
Q3 2022$47,840,0002,208,6690.04%
Other shareholders
ZENTALIS PHARMACEUTICALS INC shareholders Q4 2022
NameSharesValueWeighting ↓
Mayo Clinic 362,459$15,727,096,00018.11%
TYBOURNE CAPITAL MANAGEMENT (HK) LTD 2,664,409$115,609,0002.54%
Matrix Capital Management Company, LP 3,821,739$165,825,0001.92%
Avidity Partners Management LP 1,263,300$54,815,0001.51%
Redmile Group, LLC 2,221,044$96,371,0001.36%
Affinity Asset Advisors, LLC 77,500$3,363,0001.14%
SPHERA FUNDS MANAGEMENT LTD. 175,140$7,599,0000.58%
Eventide Asset Management 832,000$36,100,0000.54%
Integral Health Asset Management, LLC 40,000$1,736,0000.50%
VIKING GLOBAL INVESTORS LP 2,399,284$104,105,0000.31%
View complete list of ZENTALIS PHARMACEUTICALS INC shareholders